Predictive In Vitro Models in Drug Development

Venue: Mariott Courtyard

Location: Boston, Massachusetts, United States

Event Date/Time: Sep 28, 2010 End Date/Time: Sep 29, 2010
Registration Date: Sep 28, 2010
Early Registration Date: Aug 20, 2010
Report as Spam


Over 60% of drugs that fail during clinical development do so for reasons of safety. The cost implications of being able to accurately predict toxicity in vivo are huge, including:

- Reduced attrition
- Improved pipeline planning
- Less time spent in animals

Overall, finding problems with drugs that would only otherwise be uncovered during expensive clinical phases.

Predictive in vitro models provide a fantastic opportunity to more accurately predict clinical outcomes preclinic, maximizing R&D productivity and minimizing cost. But there are still some major barriers preventing their widespread adoption:

- What in vitro models are available?
- How do you assess their predictive capability?
- How do you achieve validation of new models?
- How do you best apply these models to accurately predict safety and pharmacokinetics in vivo?

Developed in collaboration with R&D leaders from Pfizer, Novartis, GSK, Roche, Abbot, Merck, Genentech, Harvard Stem Cell Institute , MIT and others, Predictive In Vitro Models for Drug Development, Boston 28th – 29th September, is designed to increase your preclinical predictive capability specifically around safety and pharmacokinetics. The meeting will bring together safety and pharmacokinetics experts from big pharma and biotech to explore how in vitro models can transform your ability to predict clinical outcomes and increase your organization's productivity.

For more information please:

Call: +44 (0) 203 1418 700

Don't forget to quote your priority booking code: ALLCONF


United States